A new ADC biotech looks to revive secretive platform, secures Big VC backing
With many companies working with antibody-drug conjugates in cancer, the newest one has two substantial backers and is looking to revitalize an old platform.
The UK outfit, unveiled early Wednesday morning, is called Pheon Therapeutics. The biotech’s stated goal is going after cancer and it is armed with $68 million, thanks to a Series A led by Forbion, Atlas Venture and Brandon Capital a few months ago. Seed investor Research Corporation Technologies also participated, per a Pheon statement.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.